Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment

被引：0
|
作者：
Ylisaukko-Oja, T. [1 ]
Af Bjorkesten, C. G. [2 ,3 ]
Erbel, A. [2 ,3 ]
Nuutinen, H. [4 ]
Jussila, A. [5 ]
Molander, P. [2 ,3 ]
Koskela, R. [6 ]
Blomster, T. [6 ]
Pajala, M. [7 ]
Ilus, T. [5 ]
Haiko, P. [8 ]
Kovac, B. [8 ]
Silvola, S. [8 ]
Smith, S. [1 ]
Jokelainen, J. [1 ]
Sipponen, T. [2 ,3 ]
机构：
[1] MedEngine Oy, Med Data Sci, Helsinki, Finland
[2] Univ Helsinki, Abdominal Ctr Gastroenterol, Helsinki, Finland
[3] Helsinki Univ Hosp, Abdominal Ctr Gastroenterol, Helsinki, Finland
[4] Turku Univ Hosp, Div Gastroenterol, Dept Med, Turku, Finland
[5] Tampere Univ Hosp, Dept Gastroenterol & Alimentary Tract Surg, Tampere, Finland
[6] Oulu Univ Hosp, Dept Med, Div Gastroenterol, Oulu, Finland
[7] Kuopio Univ Hosp, Dept Internal Med, Kuopio, Finland
[8] Takeda Oy, Helsinki, Finland
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P629
引用
收藏
页码：758 / 759
页数：2
相关论文
共 50 条
  • [31] Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina
    Mahuad C.
    Victoria O.
    Laura K.
    Enriqueta M.
    Fernando W.
    Hernán G.R.
    Nancy C.
    Dana K.
    Marta Z.
    Gonzalo G.
    de los Ángeles V.R.M.
    Florencia A.
    Erica R.B.
    Susana C.
    Eugenia F.M.
    Iliana P.
    Cecilia F.
    Anahí V.B.
    Santiago C.
    Adriana V.
    Mariela G.
    Justina L.
    Claudia C.
    Manuela C.
    Luciana M.
    Cecilia C.L.M.
    Augusto M.
    Laura F.
    Maximiliano P.
    Marcela M.
    Silvana C.
    Clinical Hematology International, 2022, 4 (1-2) : 44 - 51
  • [32] Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study
    Paksoy, Nail
    Khanmammadov, Nijat
    Dogan, Izzet
    Ferhatoglu, Ferhat
    Ahmed, Melin Aydan
    Karaman, Sule
    Aydiner, Adnan
    MEDICINE, 2023, 102 (05) : E32866
  • [33] First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice
    Kohutek, Filip
    Stratena, Miroslava
    Rosik, Andrej
    Tamasova, Maria
    Bystricky, Branislav
    LUNG CANCER MANAGEMENT, 2016, 5 (03) : 123 - 130
  • [34] REAL-LIFE LONG-TERM EFFECTIVENESS AND TREATMENT PERSISTENCE OF VEDOLIZUMAB IN A SINGLE TERTIARY CARE COHORT OF CROHN'S DISEASE PATIENTS
    Calandrini, L.
    Salice, M.
    Hrustemovic, Privitera H.
    Peruzzi, G.
    Rizzello, F.
    Calabrese, C.
    Scaioli, E.
    Belluzzi, A.
    Gionchetti, P.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S123 - S123
  • [35] COMPARISON OF REAL-WORLD TREATMENT OUTCOMES WITH INFLIXIMAB VERSUS VEDOLIZUMAB IN BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    Patel, Haridarshan
    GASTROENTEROLOGY, 2019, 156 (06) : S638 - S639
  • [36] Comparison of Real-World Treatment Outcomes With Vedolizumab Versus Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease
    Patel, Haridarshan
    Latremouille-Viau, Dominick
    Burne, Rebecca
    Shi, Sherry
    Adsul, Shashi
    CROHNS & COLITIS 360, 2019, 1 (02)
  • [37] Real-life long-term effectiveness and treatment persistence of vedolizumab in a single tertiary care cohort of Crohn's disease patients
    Calandrini, L.
    Salice, M.
    Hrustemovic, H. Privitera
    Peruzzi, G.
    Rizzello, F.
    Calabrese, C.
    Scaioli, E.
    Belluzzi, A.
    Gionchetti, P.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S347 - S348
  • [38] Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease
    Innocenti, Tommaso
    Roselli, Jenny
    Lynch, Erica N.
    Apolito, Pasquale
    Parisio, Laura
    Bagnoli, Siro
    Macri, Giuseppe
    Rogai, Francesca
    Tarocchi, Mirko
    Milani, Stefano
    Galli, Andrea
    Milla, Monica
    Dragoni, Gabriele
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E574 - E579
  • [39] Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease
    Innocenti, T.
    Roselli, J.
    Lynch, E. N.
    Apolito, P.
    Parisio, L.
    Bagnoli, S.
    Macri, G.
    Rogai, F.
    Milani, S.
    Galli, A.
    Milla, M.
    Dragoni, G.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S476 - S476
  • [40] Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease
    Innocenti, Tommaso
    Roselli, Jenny
    Lynch, Erica N. N.
    Apolito, Pasquale
    Parisio, Laura
    Bagnoli, Siro
    Macri, Giuseppe
    Rogai, Francesca
    Tarocchi, Mirko
    Milani, Stefano
    Galli, Andrea
    Milla, Monica
    Dragoni, Gabriele
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E574 - E579
12345